Paul Yasurjak

14 timestamped statements across 2 topics — auto-found in recorded discussions, each timestamp jumps to the exact moment.

Neuroblastoma · guest expert

Featured statements

▶ Ep 12 · 0:42
They reviewed patients enrolled in trials between 2007 and 2017 and found that the presence of segmental chromosomal abberations such as the loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes.
quote · Neuroblastoma
▶ Ep 12 · 0:24
The updated schema classifies tumors as high risk when there is no MYCN amplification but segmental chromosomal abnormalities are present
guideline · Neuroblastoma
▶ Ep 442 · 0:24
The presence of segmental chromosomal aberrations such as loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes
clinical · Pediatric Oncology

Nothing matches these filters — clear the search or widen the filters.

Paul's statements about Neuroblastoma 7 statements

Open the Neuroblastoma collection →

Update Course Rewind: Staging and Management of Neuroblastoma 2022

▶ Ep 12 · 0:24
guideline The Children's Oncology Group neuroblastoma classification tree is constantly changing as new information is added ↗
▶ Ep 12 · 0:24
guideline Based on the 2021 COG classification, the presented tumor would be classified as higher risk ↗
▶ Ep 12 · 0:24
epidemiological COG reviewed patients enrolled in trials between 2007 and 2017 ↗
▶ Ep 12 · 0:24
clinical The presence of segmental chromosomal aberrations such as loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes ↗
▶ Ep 12 · 0:24
guideline The updated schema classifies tumors as high risk when there is no MYCN amplification but segmental chromosomal abnormalities are present ↗
▶ Ep 12 · 0:24
quote He shared a recently updated paper from the Children's Oncology Group showing that the neuroblastoma tree is constantly changing as we're adding new information. ↗
▶ Ep 12 · 0:42
quote They reviewed patients enrolled in trials between 2007 and 2017 and found that the presence of segmental chromosomal abberations such as the loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes. ↗
Paul's statements about Pediatric Oncology 7 statements

Open the Pediatric Oncology collection →

Update Course Rewind: Staging and Management of Neuroblastoma 2022

▶ Ep 442 · 0:24
guideline The Children's Oncology Group neuroblastoma classification tree is constantly changing as new information is added ↗
▶ Ep 442 · 0:24
guideline Based on the 2021 COG classification, the presented tumor would be classified as higher risk ↗
▶ Ep 442 · 0:24
epidemiological COG reviewed patients enrolled in trials between 2007 and 2017 ↗
▶ Ep 442 · 0:24
clinical The presence of segmental chromosomal aberrations such as loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes ↗
▶ Ep 442 · 0:24
quote He shared a recently updated paper from the Children's Oncology Group showing that the neuroblastoma tree is constantly changing as we're adding new information. ↗
▶ Ep 442 · 0:24
guideline The updated schema classifies tumors as high risk when there is no MYCN amplification but segmental chromosomal abnormalities are present ↗
▶ Ep 442 · 0:42
quote They reviewed patients enrolled in trials between 2007 and 2017 and found that the presence of segmental chromosomal abberations such as the loss or gain of a portion of the chromosomal arm can have a negative impact on patient outcomes. ↗